Jonathan

Nicole

Nicole Friedland was born a long time ago in a place very far away. 1980 in Johannesburg, South Africa… When she died 19 months later, her parents had never heard of Tay-Sachs nor realized their family was at risk. Nicole’s parents Frank and Shelly spent all of their spare time looking for treatments and visiting […]

Nicole Read More »

Eli

Eli was deeply loved and cared for by multiple generations of the Capone Family during his short life. “Everybody needs to make sure they are tested, and they have done everything they can do. This is horrific, scary and a life changer,” said Laurie Capone, Eli’s grandmother.

Eli Read More »

Cristian

Born a healthy and vibrant boy, Cristian was crawling and moving around in his crib like a typical baby. At age three to six months, his parents started to notice slight developmental delays. In 2012, he was diagnosed with a terminal, untreatable, non-curable genetic disease – Tay-Sachs. Cristian’s parents immediately sought out and received a

Cristian Read More »

Jordan

On September 17, 2019, after years of searching for a diagnosis, our four year old son Jordan was diagnosed with a rare disease called TECPR2. What we would learn in the days that followed is that like Tay Sach’s Disease, TECPR2 is also a fatal genetic disease of the brain-one that will rapidly cause extreme

Jordan Read More »

Kevin Michael

Kevin Michael Vargas, born to Daniel and Sandra Vargas in 1999, was the second of three children born into the Vargas family. After about 6 months, his family would come to notice he was not developing at the normal rate of most children his age. Several tests, exams, and blood drawings later, they discovered that

Kevin Michael Read More »

Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase

“Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis”.  https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-positive-interim-safety-and

Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase Read More »

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis). Sio https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-first-patient-dosed-clinical-trial?fbclid=IwAR2DaXAujFySSmtAoEIfDF1XhG3Gi56D6CgDkbMD2yWAFQ65kP28GV3G4B0

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease Read More »

Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases

AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseases Represents Axovant’s second IND clearance for a gene therapy program in the last 12 months NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food

Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases Read More »

Scroll to Top